Figure 4.
Overview of indirectly targeted therapies that exploit aberrant chromatin remodeling in cancer. Specific vulnerabilities in cancer cells caused by loss-of-function in a chromatin-remodeling situation might be targeted for cancer therapy. Available inhibitors for each target involved in the genetic defect’s vulnerabilities conferred by aberrant chromatin remodeling are listed.